|
2014 National Pain Strategy Task Force
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, OS
|
NINDS, NIDA, NIDCR
|
A mandate to the IPRCC was to develop a National Pain Strategy for which a Task Force was established. In 2010, in response to a congressional mandate, the National Institutes of Health (NIH) contracted with the Institute of Medicine (IOM) to undertake a study and make recommendations “to increase the recognition of pain as a significant public health problem in the United States.” The Institute’s 2011 report called for a cultural transformation in pain prevention, care, education, and research and recommended development of “a comprehensive population health-level strategy” to address these issues. The Assistant Secretary for Health and Human Services (HHS) asked the Interagency Pain Research Coordinating Committee (IPRCC) to oversee creation of this resultant National Pain Strategy. Guided and coordinated by an oversight panel, expert working groups explored six important areas of need identified in the IOM recommendations—population research, prevention and care, disparities, service delivery and reimbursement, professional education and training, and public awareness and communication. The Working Groups comprised people from a broad array of relevant public and private organizations, including health care providers, insurers, and people with pain and their advocates.
|
|
2015 Dietary Guidelines Management Team
|
Other
|
ACF, CDC, FDA, HRSA, IHS, OS
|
NIDDK, NCI, OD/DPCPSI/ODP
|
The Dietary Guidelines Management Team includes federal staff representing the Departments of Health and Human Services and Agriculture throughout the Dietary Guidelines for Americans revision process and supports the Dietary Guidelines Advisory Committee from the planning phase to the final report phase.
|
|
4th Annual NICHD Infant Mortality Awareness 5-Kilometer Run/Walk/Roll
|
Meeting/ Workshop
|
OS
|
NICHD
|
Infant mortality is one of the most important indicators of the health of a nation. According to a National Center for Health Statistics data brief issued in 2013, the United States ranked 27th in the world in infant mortality. Medical research, public health outreach, and social services have helped the overall U.S. infant mortality rate to decline during the 20th century. In spite of this general decline, infant mortality rates for certain populations, including African American, Puerto Rican, and American Indian/Alaskan Native infants remain above the U.S. average of 6.05 per 1,000 live births.
The NIH is committed to conducting and supporting research that reduces the high U.S. infant mortality rate, and the disparate rates that impact communities of color. The run/walk began in front of Building 1 on the NIH main campus October 3, 2013 at 11:00 a.m. This event aiided to raise awareness about infant mortality, particularly in those communities where the rates are above the US average. During the event NICHD highlighted ongoing research efforts supported by NICHD in addressing this public health concern.
|
|
7th Annual Conference on the Science of Dissemination and Implementation
|
Meeting/ Workshop
|
AHRQ
|
NHLBI, NCCAM, NCI, NIAAA, NIAID, NIDA, NIDDK, NIMH, NINR
|
A forum for discussing the science of disseminatio and implemtation, the 7th annual conference aimed to grow the research base by bridging the gap betwene evience, practice, and policy in health and medicine.
|
|
A Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews
|
Research Initiative
|
CDC
|
NCI
|
A cross-sectional study of 83 airline pilots and 50 university faculty to assess the relation of stable chromosome translocations with cosmic radiation exposure.
|
|
A Working Group to Consider Questions Related to Preparations for Response to Ebola Epidemic
|
Research Initiative
|
OS
|
CC
|
Dr. Marion Danis is participating in a Working Group to address ethical questions related to the Ebola epidemic. This has included giving input to the manufacturers of the investigational drug ZMapp and servicing on the Ethics Panel convened by the World Health Organization
|
|
A Working Group to Consider the Question of Federal Public Health and Medical Resource Allocation
|
Committee, Work group, Advisory group, or Task Force
|
OS
|
CC
|
Dr. Marion Danis is participating in a working group to consider the question of federal public health and medical resource allocation. The group developed a framework for allocation of federal resources during scarcity after engaging with stakeholders in ethics, disaster preparedness, and emergency management.
|
|
A5295 Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects
|
Research Initiative
|
CDC
|
NIAID
|
This initiative will estimate the sensitivity of a single Xpert MTB/RIF assay (performed on sputum) in TB suspects with at least one acid fast bacilli (AFB) sputum smear positive result and at least one culture result positive for Mycobacterium tuberculosis.
|
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT)
|
Research Initiative
|
FDA
|
NIDA
|
Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) is part of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA). The mission of the (ACTTION) is to identify, prioritize, sponsor, coordinate, and promote innovative activities with a special interest in optimizing clinical trials that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of public health.
|
|
Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus
|
Research Initiative
|
FDA
|
NIAMS, NIAID
|
The National Institutes of Health (NIH), pharmaceutical companies and nonprofit organizations have together created the Accelerating Medicines Partnership (AMP) to develop new models for identifying and validating promising biological targets for new diagnostics and drug development. A major goal is to generate pre-competitive, disease-specific data that will be publicly accessible to the broad biomedical community for further research (http://www.nih.gov/science/amp/).
The partners have designed a project plan to address relevant challenges for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (AMP RA/SLE Program). The goal is to ascertain and define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of autoimmune diseases. This program will involve an enhanced systems-level understanding of gene expression and signaling in target tissues from affected end organs (synovium for RA, kidney and skin for lupus) and blood cells. The initial focus of research will be on RA and lupus, with the flexibility to expand in the future to related autoimmune diseases contingent on scientific feasibility and availability of resources.
|